Home ›
Esophageal Cancer Trials ›
NCT06329869
Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma
The goal of this clinical trial is to investigate the efficacy and safety of sacituzumab govitecan in patients with advanced esophageal squamous cell carcinoma.
Trial Details
NCT ID NCT06329869
Phase PHASE2
Sponsor National Taiwan University Hospital
Status RECRUITING
Cancer Type Esophageal Cancer
Interventions
Locations (sample) Taipei, Taiwan|25.05306,121.52639
Key Eligibility Criteria
Female or male patients, 18 years of age or older, able to understand and give written informed consent. Histologically proven squamous cell carcinoma of esophagus. Patients with advanced ESCC, defined as those with unresectable locally advanced, recurrent, or metastatic disease, failed prior platinum-based che… Measurable disease as determined by RECIST 1.1. Lesions in previously irradiated areas should not be considered measurable unless they have progres…
For full eligibility, visit ClinicalTrials.gov .